Kailera Therapeutics, Inc. (KLRA)
11.02
-0.56
(-4.84%)
USD |
NASDAQ |
Nov 20, 16:00
11.23
+0.21
(+1.91%)
After-Hours: 20:00
Kailera Therapeutics Research and Development Expense (TTM) : 283.60M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 283.60M |
| Date | Value |
|---|---|
| June 30, 2026 | 218.45M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Twist Bioscience Corp. | 71.84M |
| Prime Medicine, Inc. | 136.33M |
| GRAIL, Inc. | 183.98M |
| Oncolytics Biotech, Inc. | 13.18M |
| Sangamo Therapeutics, Inc. | 113.79M |